Morgan Stanley downgraded shares of Spire Healthcare Group (LON:SPI) to an equal weight rating in a research report report published on Friday morning, Stock Target Advisor reports. The firm currently has GBX 99 ($1.22) target price on the stock, down from their previous target price of GBX 156 ($1.92).

Other research analysts also recently issued research reports about the stock. Jefferies Financial Group restated an underperform rating and set a GBX 67 ($0.82) price objective (down previously from GBX 113 ($1.39)) on shares of Spire Healthcare Group in a research report on Wednesday, July 8th. Royal Bank of Canada downgraded shares of Spire Healthcare Group to a sector performer rating and set a GBX 100 ($1.23) price objective on the stock. in a research report on Monday, May 11th. Peel Hunt restated a buy rating on shares of Spire Healthcare Group in a research report on Wednesday, July 1st. Finally, Liberum Capital restated a hold rating on shares of Spire Healthcare Group in a research report on Thursday, July 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. Spire Healthcare Group has a consensus rating of Hold and an average target price of GBX 117.13 ($1.44).

Shares of LON SPI opened at GBX 85.10 ($1.05) on Friday. The firm’s 50 day moving average price is GBX 90.90 and its 200-day moving average price is GBX 105.98. The company has a market cap of $337.71 million and a PE ratio of 47.28. Spire Healthcare Group has a 52-week low of GBX 51.10 ($0.63) and a 52-week high of GBX 145 ($1.78). The company has a debt-to-equity ratio of 124.33, a quick ratio of 0.77 and a current ratio of 1.03.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics in the United Kingdom. It provides a range of integrated surgical, medical, and diagnostic services. The company offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.

See Also: Limitations of the P/E Growth ratio

Analyst Recommendations for Spire Healthcare Group (LON:SPI)

Receive News & Ratings for Spire Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spire Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.